Probable linagliptin-induced liver toxicity: A case report - 07/02/14
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Aim |
Unlike other dipeptidyl peptidase 4 (DPP-4) inhibitors, the excretion of linagliptin is mainly through a biliary route. Despite this fact, liver injury with linagliptin has thus far not been reported in the literature. However, this report describes the first case of probable linagliptin-induced liver toxicity.
Methods |
The clinical history, diagnosis, investigations and drug treatment of the patient are reviewed here.
Results |
A 58-year-old Japanese woman presented with fatigue, nausea, jaundice and marked elevations of hepatic enzymes 4weeks after starting linagliptin 5mg/day as monotherapy. No other medications were taken, and imaging studies revealed no other obvious causes of hepatic injury. Tests for viral serology and antinuclear antigen were negative. Symptoms disappeared and the levels of hepatic parameters (serum aminotransferases and biliary enzymes) slowly recovered after discontinuation of linagliptin. The slow recovery process may have been due to the very long half-life of the drug. The patient's Naranjo scale score was 6 and RUCAM score was 7.
Conclusion |
Although linagliptin currently carries no liver warnings, it may be necessary to monitor hepatic function in some patients upon administration of this drug until further evidence is obtained.
Le texte complet de cet article est disponible en PDF.Keywords : DPP-4 inhibitors, Linagliptin, Drug-induced liver toxicity
Plan
Vol 40 - N° 1
P. 82-84 - février 2014 Retour au numéro
Article précédent
- Abdominal obesity and low-grade systemic inflammation as markers of subclinical organ damage in type 2 diabetes
- E.M. Dahlén, A. Tengblad, T. Länne, B. Clinchy, J. Ernerudh, F.H. Nystrom, C.J. Östgren
- Concerns over the consequences of regional disparities for elderly French type 2 diabetes patients in the Gerodiab study
- J.-P. Le Floch, J. Doucet, B. Bauduceau, C. Verny, SFD/SFGG Intergroup, B Bauduceau, J-F Blicklé, I Bourdel-Marchasson, T Constans, J Doucet, A Fagot-Campagna, E Kaloustian, V Lassmann-Vague, P Lecomte, D Tessier, C Verny, U Vischer, H Affres, M Alix, F Archambeaud, Z Barrou, B Bauduceau, P Beau, S Beltran, C Benoit, J-P Beressi, F Bernachon, C Berne, G Berrut, A Blaimont, J-F Blickle, M Boda-Buccino, J Bohatier, P Böhme, L Bordier, K Bouchou, B Bouillet, F Bouilloud, R Bouix, E Boulanger, I Bourdel-Marchasson, C Bourgon, E Bourrinet, P Brocker, I Bruckert, C Capet, C Carette, B Cariou, A Carreau, C Chaillou Vaurie, S Chamouni, C Ciangura, C Collet-Gaudillat, M-E Combes-Moukhovsky, T Constans, M Cordonnier, A Cuperlier, D Dambre, J D’Avigneau, P De Botton, V Degros, F Delamarre-Damier, S Denat, F Desbiez, B Deumier, F Dorey, J Doucet, E Dresco, A Drutel, E Du Rosel De Saint Germain, D Dubois-Laforgue, B Duly-Bouhanick, O Dupuy, L Dusselier, S Faucher-Kareche, S Fendri, P Fontaine, S Galinat, A Gentric, H Gin, F Glaise, T Godeau, B Gonzales, I Got, B Guerci, P-J Guillausseau, S Hadjadj, Y Hadjali, M Halbron, S Halimi, C Halter, H Hanaire, V Hardy, A Hartemann-Heurtier, J-P Haulot, F Hequet, M Issa-Sayegh, P Jan, N Jeandidier, H Joseph-Henri, I Julier, E Kaloustian, V Kerlan, T Kharitonnoff, M Ladsous, L Lahaxe, M-P Lamaraud, E Lassenne, J-M Lecerf, P Lecomte, I Leroux, S Lesven, M Levy, S Lopez, F Makiza, P Manckoundia, C Marquis Pomeau, H Mayaudon, S Micheli, R Mira, F Monnier, H Mosnier-Pudar, N Neri, I Normand, M Paccalin, C Pagu, D Paris, A Penfornis, J-L Perie, J-M Petit, G Petit-Aubert, B Pichot-Duclos, L Pivois, M Popelier, G Poulingue, M Priner, V Quipourt, M Rasamisoa, J-L Richard, V Rigalleau, N Roudat, C Sanz, J-M Serot, D Sifi, S Sirvain, A Slimani, E Sonnet, C Sosset, A Soualah, A Stroea, I Tauveron, J Timsit, M Tschudnowsky, A Vambergue, O Verier-Mine, C Verny, M Virally
Bienvenue sur EM-consulte, la référence des professionnels de santé.